 | |
| Names | |
|---|---|
| IUPAC name (4S)-4-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-5-[[2-[[(2S)-3-carboxy-1-[[(2S)-1-[[1-[[(2S)-1-[[(2S)-4-carboxy-1-[[2-[[2-[[2-[[(2S)-1-[[(1S)-1-carboxy-4-(diaminomethylideneamino)butyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-oxopentanoic acid | |
| Other names Fibrinopeptide A; Fibrinopeptide A (human); FpA; FPA | |
| Identifiers | |
3D model (JSmol) | |
| ChemSpider | |
| |
| |
| Properties | |
| C63H97N19O26 | |
| Molar mass | 1536.57 g/mol |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
 | |
| Names | |
|---|---|
| IUPAC name (4S)-4-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-3-methyl-2-[[2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]acetyl]amino]butanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-4-oxobutanoyl]amino]-4-carboxybutanoyl]amino]-5-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-oxopentanoic acid | |
| Other names Fibrinopeptide B; Fibrinopeptide B (human); FpB; FPB | |
| Identifiers | |
3D model (JSmol) | |
| ChemSpider | |
| |
| |
| Properties | |
| C66H93N19O25 | |
| Molar mass | 1552.569 g/mol |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
Thefibrinopeptides,fibrinopeptide A (FpA) andfibrinopeptide B (FpB), arepeptides which are located in the central region of thefibrousglycoproteinfibrinogen (factor I) and arecleaved by theenzymethrombin (factor IIa) to convert fibrinogen intocovalently-linkedfibrin (factor IA)monomers.[1][2] TheN-terminal FpA is cleaved from theAα chains of fibrinogen and FpB from theBβ chains of fibrinogen, with FpA released before FpB.[3][4] Subsequent to their formation, fibrin monomers are converted to cross-linked fibrinpolymers by the action of thrombin-activatedfactor XIII (fibrin stabilizing factor), and these fibrin polymers form the backbone of athrombus (blood clot).[2] Hence, the fibrinopeptides are sensitive markers offibrinogenesis (fibrin generation),thrombin activity, andcoagulation.[5][6][7][8]
FpA is a 16-amino acid peptide.[8] Thehalf-life of FpA is very short at approximately 3 to 5 minutes.[5][8] Hence, FpA levels provide a relatively transient measure of coagulation activation.[8]
Levels of FpA increase with age.[5] FpA levels also gradually increase throughoutpregnancy.[9][10] Likewise, FpA levels have been reported to increase withestrogen therapy, including withcombined birth control pills andmenopausal hormone therapy, although research on FpA levels with these therapies appears to be relatively limited.[11][12][13][7]